Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's
disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will
examine the safety and tolerability of the drug. This study is evaluating 3 different dose
levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All
eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study
drug administration part of the study.